EP Patent

EP3170395A1 — Morphinan derivatives with high oral bioavailability

Assigned to Alkermes Pharma Ireland Ltd · Expires 2017-05-24 · 9y expired

What this patent protects

The instant application relates to morphinan derivatives of formula I with enhanced oral bioavailability for the treatment of diseases associated with opioid receptor activity or blockade including alcohol and opiate addiction.

USPTO Abstract

The instant application relates to morphinan derivatives of formula I with enhanced oral bioavailability for the treatment of diseases associated with opioid receptor activity or blockade including alcohol and opiate addiction.

Drugs covered by this patent

Patent Metadata

Patent number
EP3170395A1
Jurisdiction
EP
Classification
—
Expires
2017-05-24
Drug substance claim
No
Drug product claim
No
Assignee
Alkermes Pharma Ireland Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.